http://www.legislation.gov.uk/uksi/2006/2984/note/madeThe Medicines for Human Use (Clinical Trials) Amendment (No.2) Regulations 2006medicinesenKing's Printer of Acts of Parliament2016-06-16MEDICINES These Regulations amend the Medicines for Human Use (Clinical Trials) Regulations 2004 (the Clinical Trials Regulations) which implement Directive 2001/20/EC on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. EXPLANATORY NOTE (This note is not part of the Regulations)

These Regulations amend the Medicines for Human Use (Clinical Trials) Regulations 2004 (the Clinical Trials Regulations) which implement Directive 2001/20/EC on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use.

Regulation 28(1) of, and Schedule 1 to, the Clinical Trials Regulations implement, among other provisions, article 5(a) of that Directive, which requires that an incapacitated adult cannot be included in a clinical trial of a medicine without the consent of his legal representative.

Regulation 2 amends Schedule 1 to creates an exception to the general rule that an incapacitated adults cannot be included in a clinical trial unless the conditions in paragraphs 1 to 5 of Part 5 of Schedule 1 have been met; in particular that the adult’s legal representative (as defined) has given informed consent. The exception applies only when the following conditions are met: (i) treatment is required urgently; (ii) the nature of the trial also requires urgent action; (iii) it is not reasonably practicable to meet the conditions in paragraphs 1 to 5 of Part 5 (obtaining consent etc); and (iv) an ethics committee has given approval to the procedure under which the action is taken.

Regulation 3 amends the Adults with Incapacity (Scotland) Act 2000 consequentially.

A full regulatory impact assessment of the effect that this instrument will have on the costs of business is available from the Medicines and Healthcare products Regulatory Agency, Market Towers, 1 Nine Elms Lane, London, SW8 5NQ and copies have been placed in the library of both Houses of Parliament.

OJ No. L121, 1.5.2001, p.34.
This XML file does not appear to have any style information associated with it. The document tree is shown below.
<Legislation xmlns="http://www.legislation.gov.uk/namespaces/legislation" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" DocumentURI="http://www.legislation.gov.uk/uksi/2006/2984/made" IdURI="http://www.legislation.gov.uk/id/uksi/2006/2984" NumberOfProvisions="3" xsi:schemaLocation="http://www.legislation.gov.uk/namespaces/legislation http://www.legislation.gov.uk/schema/legislation.xsd" SchemaVersion="1.0">
<ukm:Metadata xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dct="http://purl.org/dc/terms/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:ukm="http://www.legislation.gov.uk/namespaces/metadata">
<dc:identifier>http://www.legislation.gov.uk/uksi/2006/2984/note/made</dc:identifier>
<dc:title>The Medicines for Human Use (Clinical Trials) Amendment (No.2) Regulations 2006</dc:title>
<dc:subject>medicines</dc:subject>
<dc:language>en</dc:language>
<dc:publisher>King's Printer of Acts of Parliament</dc:publisher>
<dc:modified>2016-06-16</dc:modified>
<dc:subject scheme="SIheading">MEDICINES</dc:subject>
<dc:description>These Regulations amend the Medicines for Human Use (Clinical Trials) Regulations 2004 (the Clinical Trials Regulations) which implement Directive 2001/20/EC on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use.</dc:description>
<atom:link rel="self" href="http://www.legislation.gov.uk/uksi/2006/2984/note/made/data.xml" type="application/xml"/>
<atom:link rel="http://www.legislation.gov.uk/def/navigation/resources" href="http://www.legislation.gov.uk/uksi/2006/2984/resources" title="More Resources"/>
<atom:link rel="http://www.legislation.gov.uk/def/navigation/memorandum" href="http://www.legislation.gov.uk/uksi/2006/2984/memorandum" title="Explanatory Memorandum"/>
<atom:link rel="http://www.legislation.gov.uk/def/navigation/memorandum/toc" href="http://www.legislation.gov.uk/uksi/2006/2984/memorandum/contents" title="Explanatory Memorandum Table of Contents"/>
<atom:link rel="http://www.legislation.gov.uk/def/navigation/act" href="http://www.legislation.gov.uk/uksi/2006/2984/made" title="whole act"/>
<atom:link rel="http://www.legislation.gov.uk/def/navigation/introduction" href="http://www.legislation.gov.uk/uksi/2006/2984/introduction/made" title="introduction"/>
<atom:link rel="http://www.legislation.gov.uk/def/navigation/signature" href="http://www.legislation.gov.uk/uksi/2006/2984/signature/made" title="signature"/>
<atom:link rel="http://www.legislation.gov.uk/def/navigation/note" href="http://www.legislation.gov.uk/uksi/2006/2984/note/made" title="note"/>
<atom:link rel="http://www.legislation.gov.uk/def/navigation/body" href="http://www.legislation.gov.uk/uksi/2006/2984/body/made" title="body"/>
<atom:link rel="alternate" type="application/rdf+xml" href="http://www.legislation.gov.uk/uksi/2006/2984/note/made/data.rdf" title="RDF/XML"/>
<atom:link rel="alternate" type="application/akn+xml" href="http://www.legislation.gov.uk/uksi/2006/2984/note/made/data.akn" title="AKN"/>
<atom:link rel="alternate" type="application/xhtml+xml" href="http://www.legislation.gov.uk/uksi/2006/2984/note/made/data.xht" title="HTML snippet"/>
<atom:link rel="alternate" type="text/html" href="http://www.legislation.gov.uk/uksi/2006/2984/note/made/data.htm" title="Website (XHTML) Default View"/>
<atom:link rel="alternate" type="text/csv" href="http://www.legislation.gov.uk/uksi/2006/2984/note/made/data.csv" title="CSV"/>
<atom:link rel="alternate" type="application/pdf" href="http://www.legislation.gov.uk/uksi/2006/2984/note/made/data.pdf" title="PDF"/>
<atom:link rel="alternate" type="application/akn+xhtml" href="http://www.legislation.gov.uk/uksi/2006/2984/note/made/data.html" title="HTML5 snippet"/>
<atom:link rel="http://purl.org/dc/terms/tableOfContents" hreflang="en" href="http://www.legislation.gov.uk/uksi/2006/2984/contents/made" title="Table of Contents"/>
<atom:link rel="up" href="http://www.legislation.gov.uk/uksi/2006/2984/made" title="Entire legislation"/>
<atom:link rel="prev" href="http://www.legislation.gov.uk/uksi/2006/2984/signature/made" title="Signature; Signature"/>
<atom:link rel="prevInForce" href="http://www.legislation.gov.uk/uksi/2006/2984/signature/made" title="Signature; Signature"/>
<ukm:SecondaryMetadata>
<ukm:DocumentClassification>
<ukm:DocumentCategory Value="secondary"/>
<ukm:DocumentMainType Value="UnitedKingdomStatutoryInstrument"/>
<ukm:DocumentStatus Value="final"/>
<ukm:DocumentMinorType Value="regulation"/>
</ukm:DocumentClassification>
<ukm:Year Value="2006"/>
<ukm:Number Value="2984"/>
<ukm:Made Date="2006-11-15"/>
<ukm:Laid Date="2006-11-21" Class="UnitedKingdomParliament"/>
<ukm:ComingIntoForce>
<ukm:DateTime Date="2006-12-12"/>
</ukm:ComingIntoForce>
<ukm:ISBN Value="0110753283"/>
</ukm:SecondaryMetadata>
<ukm:Notes>
<ukm:Note IdURI="http://www.legislation.gov.uk/id/uksi/2006/2984/notes"/>
<ukm:Alternatives>
<ukm:Alternative Date="2008-12-11" URI="http://www.legislation.gov.uk/uksi/2006/2984/pdfs/uksiem_20062984_en.pdf" Title="Explanatory Memorandum"/>
</ukm:Alternatives>
</ukm:Notes>
<ukm:Alternatives>
<ukm:Alternative Date="2008-12-11" URI="http://www.legislation.gov.uk/uksi/2006/2984/pdfs/uksi_20062984_en.pdf" Title="Print Version"/>
</ukm:Alternatives>
<ukm:Statistics>
<ukm:TotalParagraphs Value="3"/>
<ukm:BodyParagraphs Value="3"/>
<ukm:ScheduleParagraphs Value="0"/>
<ukm:AttachmentParagraphs Value="0"/>
<ukm:TotalImages Value="0"/>
</ukm:Statistics>
</ukm:Metadata>
<Secondary>
<ExplanatoryNotes DocumentURI="http://www.legislation.gov.uk/uksi/2006/2984/note/made" IdURI="http://www.legislation.gov.uk/id/uksi/2006/2984/note">
<Title>EXPLANATORY NOTE</Title>
<Comment>
<Para>
<Text>(This note is not part of the Regulations)</Text>
</Para>
</Comment>
<P>
<Text Hanging="indented">
These Regulations amend the Medicines for Human Use (Clinical Trials) Regulations 2004 (the
<Abbreviation Expansion="Medicines for Human Use (Clinical Trials) Regulations 2004 (S.I. 2004/1031)">Clinical Trials Regulations</Abbreviation>
) which implement Directive
<Citation URI="http://www.legislation.gov.uk/european/directive/2001/0020" id="c00002" Class="EuropeanUnionDirective" Year="2001" Number="20">
2001/20/
<Acronym Expansion="European Community">EC</Acronym>
</Citation>
on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use
<FootnoteRef Ref="f00005"/>
.
</Text>
</P>
<P>
<Text Hanging="indented">Regulation 28(1) of, and Schedule 1 to, the Clinical Trials Regulations implement, among other provisions, article 5(a) of that Directive, which requires that an incapacitated adult cannot be included in a clinical trial of a medicine without the consent of his legal representative.</Text>
</P>
<P>
<Text Hanging="indented">
Regulation 2 amends Schedule 1 to creates an exception to the general rule that an incapacitated adults cannot be included in a clinical trial unless the conditions in paragraphs 1 to 5 of Part 5 of Schedule 1 have been met; in particular that the adult’s legal representative (as defined) has given informed consent. The exception applies only when the following conditions are met: (i) treatment is required urgently; (ii) the nature of the trial also requires urgent action; (iii) it is not reasonably practicable to meet the conditions in paragraphs 1 to 5 of Part 5 (obtaining consent
<Abbreviation Expansion="Et cetera" xml:lang="la">etc</Abbreviation>
); and (iv) an ethics committee has given approval to the procedure under which the action is taken.
</Text>
</P>
<P>
<Text Hanging="indented">Regulation 3 amends the Adults with Incapacity (Scotland) Act 2000 consequentially.</Text>
</P>
<P>
<Text Hanging="indented">A full regulatory impact assessment of the effect that this instrument will have on the costs of business is available from the Medicines and Healthcare products Regulatory Agency, Market Towers, 1 Nine Elms Lane, London, SW8 5NQ and copies have been placed in the library of both Houses of Parliament.</Text>
</P>
</ExplanatoryNotes>
</Secondary>
<Footnotes>
<Footnote id="f00005">
<FootnoteText>
<Para>
<Text>
<Acronym Expansion="Official Journal">OJ</Acronym>
<Abbreviation Expansion="Number">No.</Abbreviation>
L121, 1.5.2001, p.34.
</Text>
</Para>
</FootnoteText>
</Footnote>
</Footnotes>
</Legislation>